Kodiak Sciences - KOD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.22
  • Forecasted Upside: 376.61 %
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.14 (-1.81%)

This chart shows the closing price for KOD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kodiak Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KOD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KOD

Analyst Price Target is $36.22
▲ +376.61% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $36.22, with a high forecast of $114.00 and a low forecast of $9.00. The average price target represents a 376.61% upside from the last price of $7.60.

This chart shows the closing price for KOD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Kodiak Sciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $12.00Low
8/10/2022Chardan CapitalLower TargetBuy$19.00 ➝ $18.00Low
8/9/2022Truist FinancialBoost TargetBuy$10.00 ➝ $15.00Low
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$9.00Low
8/2/2022CitigroupDowngradeNeutral ➝ SellLow
4/12/2022Morgan StanleyLower TargetEqual Weight$17.00 ➝ $12.00Medium
4/11/2022Chardan CapitalReiterated RatingBuyHigh
3/29/2022Chardan CapitalLower Target$82.50 ➝ $19.00High
2/28/2022Roth CapitalLower Target$149.00 ➝ $75.00Medium
2/24/2022Truist FinancialLower Target$147.00 ➝ $35.00Medium
2/24/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $17.00High
2/24/2022CitigroupLower TargetNeutral$70.00 ➝ $12.00High
2/24/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$90.00 ➝ $21.00High
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$70.00High
2/7/2022BarclaysLower TargetUnderweight$81.00 ➝ $50.00Medium
2/2/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$124.00 ➝ $90.00High
2/1/2022Morgan StanleyLower TargetEqual Weight$122.00 ➝ $77.00Low
1/26/2022CitigroupLower TargetNeutral$114.00 ➝ $70.00High
1/18/2022Morgan StanleyBoost TargetEqual Weight$119.00 ➝ $122.00Low
11/12/2021BMO Capital MarketsBoost TargetMarket Perform$104.00 ➝ $114.00Medium
11/11/2021CitigroupBoost TargetNeutral$103.00 ➝ $114.00Low
5/11/2021Roth CapitalUpgradeNeutral ➝ Buy$155.00 ➝ $149.00High
5/11/2021BMO Capital MarketsLower TargetMarket Perform$138.00 ➝ $104.00High
5/11/2021BarclaysLower TargetUnderweight$90.00 ➝ $86.00High
5/4/2021Truist FinancialBoost TargetBuy$89.00 ➝ $147.00High
4/19/2021Morgan StanleyLower TargetEqual Weight$133.00 ➝ $119.00Low
3/11/2021Evercore ISIInitiated CoverageOutperformHigh
3/8/2021Morgan StanleyBoost TargetEqual Weight$125.00 ➝ $133.00High
3/8/2021BarclaysReiterated RatingEqual Weight ➝ Underweight$52.00 ➝ $90.00Medium
3/2/2021BMO Capital MarketsLower TargetMarket Perform$148.00 ➝ $138.00Medium
3/1/2021BarclaysDowngradeEqual Weight ➝ Underweight$52.00 ➝ $90.00Low
2/17/2021Roth CapitalDowngradeBuy ➝ Neutral$133.00 ➝ $155.00Low
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$145.00 ➝ $148.00High
12/17/2020Berenberg BankInitiated CoverageBuy$156.00Medium
12/15/2020UBS GroupInitiated CoverageBuy$170.00Medium
12/11/2020Smith Barney CitigroupInitiated CoverageNeutral$134.00High
11/30/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$74.00 ➝ $125.00High
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$80.00 ➝ $125.00Low
11/13/2020BMO Capital MarketsBoost TargetOutperform$74.00 ➝ $145.00High
11/13/2020The Goldman Sachs GroupDowngradeNeutral$105.00Medium
11/10/2020Roth CapitalBoost TargetBuy$124.00 ➝ $133.00High
11/9/2020Roth CapitalBoost TargetBuy$115.00 ➝ $133.00High
7/28/2020SunTrust BanksLower TargetBuy$90.00 ➝ $89.00Low
5/14/2020SunTrust BanksLower TargetBuy$101.00 ➝ $90.00High
4/15/2020Morgan StanleyLower TargetOverweight$82.00 ➝ $80.00Low
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$74.00High
3/2/2020The Goldman Sachs GroupInitiated CoverageBuy$80.00Medium
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$69.00Medium
2/5/2020SunTrust BanksInitiated CoverageBuy$101.00High
1/23/2020Chardan CapitalReiterated RatingBuyHigh
1/8/2020Roth CapitalInitiated CoverageBuy$115.00Medium
1/3/2020HC WainwrightInitiated CoverageBuy$100.00Low
1/3/2020Jefferies Financial GroupInitiated CoverageBuy$100.00Low
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$82.00High
12/17/2019Morgan StanleyBoost TargetOverweight$33.00 ➝ $82.00High
12/2/2019Chardan CapitalReiterated RatingBuy$40.00High
11/13/2019Chardan CapitalReiterated RatingBuy$40.00High
10/15/2019Chardan CapitalBoost TargetBuy$22.50 ➝ $35.00High
6/13/2019Chardan CapitalReiterated RatingBuy$22.50Low
2/20/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$22.50Medium
10/29/2018BarclaysInitiated CoverageOverweight ➝ Overweight$20.00High
10/29/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00High
10/29/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$14.00High
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 10 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.
Kodiak Sciences logo
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Read More

Today's Range

Now: $7.60
Low: $7.34
High: $7.91

50 Day Range

MA: $9.87
Low: $7.57
High: $12.50

52 Week Range

Now: $7.60
Low: $4.90
High: $26.39


395,945 shs

Average Volume

488,652 shs

Market Capitalization

$395.50 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Kodiak Sciences?

The following Wall Street research analysts have issued research reports on Kodiak Sciences in the last twelve months: Barclays PLC, BMO Capital Markets, Chardan Capital, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Roth Capital, The Goldman Sachs Group, Inc., and Truist Financial Co..
View the latest analyst ratings for KOD.

What is the current price target for Kodiak Sciences?

9 Wall Street analysts have set twelve-month price targets for Kodiak Sciences in the last year. Their average twelve-month price target is $36.22, suggesting a possible upside of 376.6%. BMO Capital Markets has the highest price target set, predicting KOD will reach $114.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $9.00 for Kodiak Sciences in the next year.
View the latest price targets for KOD.

What is the current consensus analyst rating for Kodiak Sciences?

Kodiak Sciences currently has 2 sell ratings, 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KOD, but not buy more shares or sell existing shares.
View the latest ratings for KOD.

What other companies compete with Kodiak Sciences?

Other companies that are similar to Kodiak Sciences include Mesoblast, Ocugen, C4 Therapeutics, bluebird bio and MeiraGTx. Learn More about companies similar to Kodiak Sciences.

How do I contact Kodiak Sciences' investor relations team?

Kodiak Sciences' physical mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The company's listed phone number is (650) 281-0850 and its investor relations email address is [email protected] The official website for Kodiak Sciences is kodiak.com. Learn More about contacing Kodiak Sciences investor relations.